<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Technical aspects of nocturnal hemodialysis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Technical aspects of nocturnal hemodialysis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Technical aspects of nocturnal hemodialysis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Christopher Chan, MD, FRCPC
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Steve J Schwab, MD, FACP, FASN
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Eric N Taylor, MD, MSc, FASN
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 12, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION AND OVERVIEW
         </span>
         <span class="headingEndMark">
          —
         </span>
         The mortality rate of patients undergoing maintenance hemodialysis is unacceptably high [
         <a href="#rid1">
          1
         </a>
         ]. A high morbidity, relatively low quality of life (due in part to a high level of dependence and unemployment), and high cost of care have also been observed.
        </p>
        <p>
         The Hemodialysis (HEMO) study found that increasing the dialysis dose within the general restrictions of a thrice-weekly regimen failed to decrease patient mortality [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1847.html" rel="external">
          "Patient survival and maintenance dialysis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1836.html" rel="external">
          "Prescribing and assessing adequate hemodialysis"
         </a>
         .)
        </p>
        <p>
         Instituting more intensive dialysis regimens appears to improve morbidity and possibly mortality in this patient population [
         <a href="#rid3">
          3-8
         </a>
         ]. Compared with conventional thrice weekly regimens, for example, dialysis associated with longer duration and/or higher frequency correlates with improved outcomes.
        </p>
        <p>
         Given these findings, nocturnal hemodialysis (eg, long nightly home hemodialysis) was introduced as a (possibly) more desirable alternative to conventional dialysis since it provides superior dialysis based upon dose, duration, and frequency. This can be accomplished because it is performed during nightly sleep, an otherwise unproductive time [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         A description of nocturnal hemodialysis, particularly the exact regimen associated with the procedure, will be presented here. Outcomes associated with nocturnal hemodialysis and an overview of short daily hemodialysis are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/1959.html" rel="external">
          "Outcomes associated with nocturnal hemodialysis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1898.html" rel="external">
          "Short daily hemodialysis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          DIALYSIS REGIMEN AND PRESCRIPTION
         </span>
        </p>
        <p class="headingAnchor" id="H541554921">
         <span class="h2">
          Regimen schedule
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nocturnal hemodialysis is performed either at home or in a dialysis facility. When it is done at home, the frequency of dialysis varies from three to seven nights per week. Facility-based nocturnal hemodialysis is performed three nights per week [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Required personnel
         </span>
         <span class="headingEndMark">
          —
         </span>
         Facility-based dialysis is usually performed by the attending staff. Home dialysis is performed by the patient or a helper (unpaid or paid). A partner is
         <strong>
          not
         </strong>
         absolutely required for nocturnal dialysis at home, since this procedure is associated with significant hemodynamic stability.
        </p>
        <p class="headingAnchor" id="H3859680922">
         <span class="h2">
          Hemodialysis machines
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nocturnal hemodialysis can be performed with any hemodialysis machine. Attractive attributes of a home hemodialysis machine include ease of operation and disinfection, single-needle system, low noise level, an easily accessible screen that dims at night, a back-up battery to protect from power failure, and the ability to monitor the patient remotely.
        </p>
        <p>
         Home hemodialysis machines can be high or low dialysate flow machines. Machines that have been approved for home hemodialysis in the United States are the Fresenius 2008K, NxStage System One and One S, and Tablo [
         <a href="#rid11">
          11
         </a>
         ]. Additional details regarding these machines are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1875.html" rel="external">
          "Home hemodialysis (HHD): Establishment of a program", section on 'Dialysis equipment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H252712576">
         <span class="h2">
          Dialyzer membrane
         </span>
         <span class="headingEndMark">
          —
         </span>
         Any dialyzer membrane can be used, including smaller surface area dialyzers. Although there are no published data favoring one type of dialyzer membrane over others, most centers use high-flux dialyzers.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Time
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nocturnal hemodialysis is performed during sleep for a variable amount of time (usually six to eight hours), depending upon the length of sleep desired. For facility-based dialysis, the duration of the dialysis session is generally also dictated by facility logistics.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Dialysate composition
         </span>
         <span class="headingEndMark">
          —
         </span>
         The composition of the dialysate varies with the type of dialysis machine (high or low flow).
        </p>
        <p class="headingAnchor" id="H1027839174">
         <span class="h3">
          High dialysate flow (conventional) machines
         </span>
         <span class="headingEndMark">
          —
         </span>
         The typical composition of the dialysate for a conventional, high dialysate flow machine is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sodium – 138 mEq (mmol)/L.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Potassium – 2 to 3 mEq (mmol)/L.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bicarbonate – 30 mEq (mmol)/L for nightly regimen and 35 mEq (mmol)/L for every other night or thrice-weekly regimens.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Calcium – 2.5 to 4 mEq/L (1.25 to 2 mmol/L), with an average of 3.2 mEq/L (1.6 mmol/L). The dialysate calcium concentration is adjusted to keep parathyroid hormone (PTH) levels in the desirable range while maintaining normal predialysis calcium concentrations. The dialysate calcium concentration can be adjusted by varying the amount of
         <a class="drug drug_general" data-topicid="9186" href="/z/d/drug information/9186.html" rel="external">
          calcium chloride
         </a>
         powder that the patient adds to the dialysate (eg, 7 mL of calcium chloride powder added to 4 L of acid dialysate concentrate increases calcium concentration by approximately 0.5 mEq/L [0.25 mmol/L]).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A higher dialysate calcium is prescribed in patients with high ultrafiltration volumes to prevent a negative calcium balance. This is because the removal of calcium (ionized) with hemodialysis is generally proportionate to the volume of the fluid ultrafiltered [
         <a href="#rid12">
          12
         </a>
         ]. Pregnancy or hungry bone syndrome also requires higher levels of dialysate calcium [
         <a href="#rid13">
          13
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2070.html" rel="external">
          "Hungry bone syndrome following parathyroidectomy in patients with end-stage kidney disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Phosphate – 0 to 4.5 mg/dL (0 to 1.5 mmol/L), typically 1.2 mg/dL (0.4 mmol/L).
         <a class="drug drug_general" data-topicid="10269" href="/z/d/drug information/10269.html" rel="external">
          Sodium phosphate
         </a>
         (in the form of Fleet enema) is added, if needed, into the acid or bicarbonate concentrate. The dialysate phosphate concentration is adjusted to maintain pre- and postdialysis phosphate concentrations within the normal range. The typical dose is 30 to 60 mL per dialysate concentrate jug, but amounts as high as 200 mL can be used as a source of phosphate for those with higher requirements, such as patients who are pregnant or have hungry bone syndrome [
         <a href="#rid13">
          13,14
         </a>
         ]. Calcium and phosphate do not precipitate in the acidic pH of the concentrate [
         <a href="#rid15">
          15
         </a>
         ]. Patients on intermittent nocturnal hemodialysis are less likely to need the phosphate additive.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2823996138">
         <span class="h3">
          Low dialysate flow machines
         </span>
         <span class="headingEndMark">
          —
         </span>
         The dialysate composition of a low dialysate flow machine (ie, NxStage) is fixed and cannot be varied during the dialysis session.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sodium – 140 mEq (mmol)/L
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Potassium – 1 or 2 mEq (mmol)/L
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lactate – 40 or 45 mEq (mmol)/L
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Calcium – 3 mEq (1.5 mmol)/L
        </p>
        <p>
        </p>
        <p>
         Depending on the dialysate volume used, the higher lactate concentration of 45 mEq/L used with low dialysate flow machines may increase serum bicarbonate excessively [
         <a href="#rid16">
          16
         </a>
         ]. No dialysate additives are possible with the NxStage machine.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Blood and dialysate flow rates
         </span>
         <span class="headingEndMark">
          —
         </span>
         With conventional dialysis machines, a blood flow as low as or below 200 mL/min is adequate for most patients undergoing nocturnal hemodialysis. However, a blood flow of 200 to 300 mL/min is more typical.
        </p>
        <p>
         The blood flow rate with low dialysate flow machines (ie, NxStage) is kept high (&gt;300 mL/min) to maintain the widest blood-to-dialysate solute gradient.
        </p>
        <p>
         The dialysate flow rate is variable and depends upon the dialysis machine being used. For high dialysate flow machines, the dialysate flow ranges from 100 to 800 mL/min.
        </p>
        <p>
         The dialysate flow in a low dialysate flow machine cannot be lower than 63 mL/min. Thus, the total dialysate volume needs to be adjusted to accommodate the desired length of the treatment [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H155351781">
         <span class="h2">
          Adequacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For nocturnal hemodialysis, dialysis adequacy is usually not a concern. The minimum recommended dialysis dose, which follows the current Dialysis Outcomes Quality Initiative (DOQI) guidelines, is a standard weekly Kt/Vurea value of approximately 2 for all dialysis methods (see
         <a class="medical medical_review" href="/z/d/html/1898.html" rel="external">
          "Short daily hemodialysis", section on 'Measures of adequacy'
         </a>
         ). With conventional, high dialysate flow machines, the standard weekly Kt/V achieved with nocturnal hemodialysis is typically &gt;3 and may be &gt;5 depending on the number of sessions per week [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
         However, patients using low dialysate flow machines may have lower standard weekly Kt/V values depending on dialysate volumes, frequency, and duration. (See
         <a class="medical medical_review" href="/z/d/html/14021.html" rel="external">
          "Short daily home hemodialysis: The low dialysate volume approach", section on 'Frequent low-volume dialysate'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Ultrafiltration
         </span>
         <span class="headingEndMark">
          —
         </span>
         The typical volume of ultrafiltrate removed per day is approximately 1 to 2 liters, but larger volumes are well tolerated. Patients weigh themselves daily to maintain dry weight, which is defined as normotension without the need for antihypertensive medications or edema.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Dialyzer reuse
         </span>
         <span class="headingEndMark">
          —
         </span>
         Delayed dialyzer reprocessing has been used [
         <a href="#rid19">
          19,20
         </a>
         ]. Some dialysis machines used in situ dialyzer reprocessing [
         <a href="#rid21">
          21
         </a>
         ]. Most of the centers use new dialyzers.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Anticoagulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         To maintain systemic anticoagulation, the standard heparin regimen is the administration of approximately 1000 units of heparin per hour.
         <a class="drug drug_general" data-topicid="9320" href="/z/d/drug information/9320.html" rel="external">
          Danaparoid
         </a>
         and
         <a class="drug drug_general" data-topicid="8765" href="/z/d/drug information/8765.html" rel="external">
          argatroban
         </a>
         have also been used successfully in the case of heparin allergy [
         <a href="#rid22">
          22
         </a>
         ]. A single dose of low-molecular-weight heparin at the beginning of dialysis has been successfully used [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Access
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both central venous catheters and peripheral vascular accesses have been successfully used for nocturnal hemodialysis. When peripheral accesses are used, however, more frequent access cannulation may result in decreased access survival. This was suggested by the Frequent Hemodialysis Network (FHN) Daily and Nocturnal trials, in which the primary vascular outcome was the time to first access event (including repair, loss of access, or access-related hospitalization), and the secondary vascular outcome was the time to all repairs and time to all losses [
         <a href="#rid24">
          24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1959.html" rel="external">
          "Outcomes associated with nocturnal hemodialysis", section on 'Vascular access complications'
         </a>
         .)
        </p>
        <p>
         In the FHN Nocturnal trial, 87 participants were randomly assigned to receive in-center, six days per week hemodialysis or conventional, three days per week hemodialysis [
         <a href="#rid24">
          24
         </a>
         ]. Compared with conventional dialysis, there was a nonsignificant trend toward a higher rate of first access events associated with nocturnal dialysis (32 versus 58 events per 100 patient years, respectively; hazard ratio [HR] 1.81, 95% CI 0.94-3.48). When patients with a tunneled catheter were excluded from the analysis, nocturnal dialysis was associated with a significantly increased risk of a first access event (HR 3.23, 95% CI 1.07-10.34). In the FHN Daily trial (n = 245 participants), there was a higher incidence of a first access event in the daily group compared with the conventional group. The FHN Daily trial is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1898.html" rel="external">
          "Short daily hemodialysis", section on 'Vascular access'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          Catheters
         </span>
         <span class="headingEndMark">
          —
         </span>
         Any type of central venous catheter can be used for nocturnal hemodialysis. The capability of the catheter to provide blood flow &gt;200 mL/min is not important for most patients. A safe connection for the central catheter includes the use of pre-perforated catheter caps, which are not removed during dialysis [
         <a href="#rid9">
          9,25,26
         </a>
         ]. Careful taping of the catheter-tubing connection is of paramount importance. Accidental disconnection of the venous limb can cause exsanguination without triggering machine alarms.
        </p>
        <p class="headingAnchor" id="H541554937">
         <span class="h4">
          Complications
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thrombosis
         </strong>
         – The local instillation of 2 mg of
         <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">
          alteplase
         </a>
         (tissue-type plasminogen activator [tPA]) has been successful in restoring adequate blood flow in thrombosed catheters. The instillation of lyophilized tPA has been practiced successfully by patients at home. The approach to the prevention of catheter thrombosis is variable in different centers. The prophylactic use of tPA has been advocated to prevent catheter thrombosis [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infection
         </strong>
         – Dialysis catheter-related infections can occur among patients who perform home hemodialysis using a temporary or tunneled dialysis catheter. In one study of 98 patients on nocturnal hemodialysis using catheters, 64 percent developed bacteremia over approximately seven years; the most commonly isolated organism was
         <em>
          Staphylococcus epidermidis
         </em>
         (51 percent) [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The frequency of such infections in patients on home hemodialysis may be comparable to that in patients on in-center hemodialysis. As an example, in one study comparing the rate of first catheter infections among these groups, patients on home hemodialysis had somewhat fewer infections (1.77 versus 2.03 per 100 patient-months), although the difference between the two groups was not statistically significant [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The diagnosis and management of tunneled dialysis catheter-related infections are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/122940.html" rel="external">
          "Tunneled hemodialysis catheter-related bloodstream infection (CRBSI): Epidemiology, pathogenesis, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1966.html" rel="external">
          "Tunneled hemodialysis catheter-related bloodstream infection (CRBSI): Management and prevention"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          Fistulas and grafts
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Arteriovenous fistulas
         </strong>
         – An arteriovenous fistula is the access of choice. The standard steel needles, blunt needles, and plastic cannulas have been used successfully. Patients on home nocturnal dialysis should receive structured training and supervision during their initial cannulation attempts and, thereafter, regular training updates to maintain cannulation competency and mitigate the risks of infections and cannulation injuries.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There are two cannulation techniques commonly used for accessing the fistula:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Rope-ladder technique
         </strong>
         – The rope-ladder technique involves systematic insertion of needles at different sites for each hemodialysis treatment [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Buttonhole technique
         </strong>
         – The buttonhole technique involves the insertion of the needle/cannula through exactly the same hole and at the same angle and depth of penetration [
         <a href="#rid31">
          31-33
         </a>
         ]. After 8 to 10 cannulations (or 12 to 14 in patients with diabetes) using the buttonhole method, an epithelialized track develops that allows the use of blunt needles [
         <a href="#rid32">
          32
         </a>
         ]. Sharp needles should be used for the first week, followed by blunt needles thereafter.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Most experts and the 2019 Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines recommend rope-ladder cannulation as preferred cannulation for arteriovenous fistulas and limiting buttonhole cannulation to special circumstances given its associated increased risks of infection and related adverse consequences (see
         <a class="medical medical_review" href="/z/d/html/112108.html" rel="external">
          "Overview of hemodialysis arteriovenous fistula maintenance and thrombosis prevention", section on 'Standard versus buttonhole technique'
         </a>
         ) [
         <a href="#rid34">
          34
         </a>
         ]. As such, patients receiving in-center nocturnal hemodialysis typically are cannulated via the rope-ladder technique.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, the risk of infection associated with buttonhole cannulation may be mitigated with topical
         <a class="drug drug_general" data-topicid="9668" href="/z/d/drug information/9668.html" rel="external">
          mupirocin
         </a>
         prophylaxis [
         <a href="#rid33">
          33
         </a>
         ], and the buttonhole technique is a reasonable approach for select patients on home nocturnal hemodialysis who have excellent hygiene and one or more of the following characteristics:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         An arteriovenous fistula with only a small segment available for cannulation
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Substantial pain or fear associated with the rope-ladder technique
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         An arteriovenous fistula with an enlarging or large aneurysm
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Arteriovenous grafts
         </strong>
         – Arteriovenous grafts may be used successfully for nocturnal hemodialysis. The buttonhole technique is not practiced with these accesses. A different hole is used with every dialysis, following the conventional technique. Steel needles or plastic cannulas can be used.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Single-needle dialysis
         </strong>
         – For patients on home nocturnal hemodialysis who dialyze via an arteriovenous fistula or graft, some home nocturnal hemodialysis programs use a single-needle technique to minimize the number of access punctures. The single-needle system provides adequate blood flow (average 200 mL/min), while providing extra safety in case of accidental disconnection by triggering an air detection alarm.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H14090534">
         <span class="h1">
          SAFETY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Safety while on home hemodialysis is of paramount importance [
         <a href="#rid35">
          35
         </a>
         ]. Home hemodialysis is generally considered to be safe, provided that patients are carefully selected, are well-trained, and observe prescribed safety measures. In one report from two adult home hemodialysis programs in Canada, there was one death and six potentially fatal events among 190 patients and approximately 500 patient-years of treatment; six of the seven events involved bleeding, and five of seven involved a human error with a lapse in established protocol [
         <a href="#rid36">
          36
         </a>
         ]. In another observational study, severe adverse events were rare (0.009 per patient-year of home hemodialysis) and predominantly related to needle dislodgement or air embolism [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
         To ensure the safety of the procedure, adequate taping of the needle and anchoring of the blood tubing are essential; enuresis pads wrapped around the connection are also considered essential [
         <a href="#rid38">
          38
         </a>
         ]. Two inexpensive moisture sensors are placed strategically on the floor to detect dialysate and blood leaks. Blood leaks trigger an audible alarm. Dedicated disposable leak sensors are available, as well as nondisposable wireless leak sensors that stop the blood pump when triggered. Additional technologic updates have been developed, such as a clamp connected to a blood-loss sensor that clamps the venous line upon sensing moisture and forcing the dialysis machine to stop and alarm [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         As noted above, a single-needle system provides extra safety in case of accidental disconnection by triggering an air detection alarm. (See
         <a class="local">
          'Fistulas and grafts'
         </a>
         above.)
        </p>
        <p>
         Some centers practice live remote monitoring of patients at home [
         <a href="#rid38">
          38,40,41
         </a>
         ]. All the information available on the dialysis machine, including conditions that trigger alarms, is available to an observer at the center. The patient who is not awakened by the alarm is called.
        </p>
        <p>
         Live monitoring provides the following benefits:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Helps prevent blood from clotting in an idle extracorporeal system
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Provides reassurance to the patient
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ensures compliance
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aids the collection of data
        </p>
        <p>
        </p>
        <p>
         Despite these benefits, such monitoring has not yet detected life-threatening conditions. Thus, its use should be considered optional [
         <a href="#rid42">
          42
         </a>
         ]. Most centers do not practice remote monitoring of patients on nocturnal hemodialysis, although some centers use remote monitoring for selected patients or for short periods of time (three months).
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h1">
          PATIENT SELECTION AND TRAINING
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients capable of performing home hemodialysis or those with home helpers are eligible for nocturnal hemodialysis. Exclusion criteria include acute illnesses, uncontrolled seizure activity, labile type 1 diabetes (in the absence of a helper), and a contraindication to systemic anticoagulation [
         <a href="#rid42">
          42
         </a>
         ]. The presence of older age, an unstable cardiovascular system, hypotension, diabetes mellitus, and/or ascites are all indications, and not contraindications, for nocturnal hemodialysis. An aid to facilitate the home dialysis choice for patients has been published [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
         Patient groups that can be preferentially targeted for nocturnal hemodialysis include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Incident patients followed in a chronic kidney disease (CKD) clinic. To prevent the state of dependence frequently encountered in in-center dialysis units, training should be instituted early or patients should be dialyzed temporarily in self-care settings. Use of transitional care unit settings is increasing and may lead to an increase in the number of patients opting for home hemodialysis [
         <a href="#rid44">
          44,45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients ineligible for kidney transplantation. Nocturnal hemodialysis can be viewed as the dialysis modality closest to kidney transplantation [
         <a href="#rid46">
          46,47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with significant morbidity, including cardiac disease, diabetes mellitus, severe hypertension, intradialytic hypotension, dialysis-related symptoms, or large intradialytic weight gains.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who require conversion from peritoneal dialysis to hemodialysis and who want to maintain independence.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Large-size patients or patients not adequately dialyzed because of poor access flow.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Refractory hyperkalemia or hyperphosphatemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who are unable to meet fluid and diet restriction goals, or who wish to liberalize their dietary intake.
        </p>
        <p>
        </p>
        <p>
         All patients interested in home nocturnal hemodialysis must understand and agree to the requirements of the training program. As part of a competency assessment, patients must be evaluated for their visual acuity, dexterity, physical fitness, and home environment. (See
         <a class="medical medical_review" href="/z/d/html/1874.html" rel="external">
          "Choosing home hemodialysis for end-stage kidney disease"
         </a>
         .)
        </p>
        <p>
         Details regarding training of patients for home hemodialysis are presented at length elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1875.html" rel="external">
          "Home hemodialysis (HHD): Establishment of a program", section on 'Training of the patient'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1874.html" rel="external">
          "Choosing home hemodialysis for end-stage kidney disease"
         </a>
         .)
        </p>
        <p>
         The adoption of nocturnal hemodialysis may be hampered by patient-perceived barriers, including lack of confidence in their ability to perform necessary duties (eg, self-cannulation), fear of a possible catastrophic event, and the reluctance to burden family members or caregivers [
         <a href="#rid48">
          48
         </a>
         ]. Financial barriers can be significant [
         <a href="#rid49">
          49
         </a>
         ]. Costs include increased home utility fees for the patients and low dialysis reimbursement rates, especially when more than thrice-weekly dialysis is planned. (See
         <a class="medical medical_review" href="/z/d/html/1875.html" rel="external">
          "Home hemodialysis (HHD): Establishment of a program", section on 'Barriers to implementation of HHD'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4254835727">
         <span class="h1">
          MAINTAINING PATIENTS ON NOCTURNAL HEMODIALYSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Specific strategies to prevent technique failure among patients on home hemodialysis are necessary. According to 2022 United States Renal Data System (USRDS) data, the longevity of home hemodialysis as a modality is only about 30 percent after 24 months  (
         <a class="graphic graphic_figure graphicRef143600" href="/z/d/graphic/143600.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H2266106167">
         <span class="h2">
          Reasons for technique discontinuation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both psychosocial and medical reasons can lead to discontinuation of home nocturnal hemodialysis. Risk factors for home hemodialysis discontinuation include older age, cardiac disease, diabetes, drug use, alcohol, and smoking [
         <a href="#rid50">
          50-52
         </a>
         ]. In one report of patients who exited a home hemodialysis program, medical instability was the predominant reason for modality change (65 percent), followed by patient or caregiver burnout (13 and 6 percent, respectively) and patient choice (9 percent) [
         <a href="#rid53">
          53
         </a>
         ]. In another study, the primary reasons for switching from home hemodialysis were medical issues, lack of motivation, lack of confidence, and inability to cope with stress [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1787773056">
         <span class="h2">
          Strategies for prevention of technique failure in nocturnal hemodialysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Key strategies to maintain patients on home nocturnal hemodialysis include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Addressing psychosocial needs
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Providing multidisciplinary extra support and monitoring
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Focusing on patient education and training
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Improving physician expertise
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nocturnal hemodialysis regimen and personnel
         </strong>
         – Nocturnal hemodialysis can be practiced in the facility (thrice weekly) or at home (three to seven nights per week). Home nocturnal hemodialysis is performed either by the patient or partner (a partner not being absolutely required) during sleep for a variable amount of time, based upon the length of sleep desired (usually 6 to 8 hours in total). (See
         <a class="local">
          'Required personnel'
         </a>
         above and
         <a class="local">
          'Time'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dialysis prescription
         </strong>
         – Compared with conventional hemodialysis and depending on the frequency, the dialysate contains lower levels of bicarbonate, higher levels of calcium, and often contains phosphate. Typical flow rates are a blood flow rate of 200 to 300 mL/min and a dialysate flow rate of 300 mL/min. The typical volume of ultrafiltrate removed per day is approximately 1 to 2 liters, but higher volumes are well tolerated. (See
         <a class="local">
          'Dialysate composition'
         </a>
         above and
         <a class="local">
          'Ultrafiltration'
         </a>
         above and
         <a class="local">
          'Blood and dialysate flow rates'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anticoagulation and access
         </strong>
         – To maintain systemic anticoagulation, the standard heparin regimen is the administration of approximately 1000 units of heparin per hour. Central venous catheters, arteriovenous fistulas, and arteriovenous grafts have been successfully used for nocturnal hemodialysis. Safety devices are important to prevent accidental access disconnection and bleeding during sleep. An arteriovenous fistula is the preferred vascular access. (See
         <a class="local">
          'Anticoagulation'
         </a>
         above and
         <a class="local">
          'Access'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Safety
         </strong>
         – Some centers practice live remote monitoring of patients at home, either via regular telephone lines or the internet, while others do not practice remote monitoring. Its use should be considered optional. (See
         <a class="local">
          'Safety'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient selection and training
         </strong>
         – All patients capable of performing home hemodialysis are eligible for nocturnal hemodialysis. Exceptions include acute illnesses, uncontrolled seizures, labile type 1 diabetes in the absence of a helper, and contraindication to systemic anticoagulation. Significant comorbidities can be indications rather than contraindications for nocturnal hemodialysis. (See
         <a class="local">
          'Patient selection and training'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Maintaining patients on nocturnal hemodialysis
         </strong>
         – Key strategies to maintain patients on home nocturnal hemodialysis include addressing psychosocial patient needs, providing multidisciplinary support and monitoring, focusing on patient education and training, and improving physician expertise.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1646235756">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         We are saddened by the death of Andreas Pierratos, MD, FRCPC, who passed away in November 2022. UpToDate wishes to acknowledge Dr. Pierratos' many valuable contributions, including his past work as an author for this topic.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          United States Renal Data System. 2020 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. United States Renal Data System; National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 2020.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347:2010.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saran R, Bragg-Gresham JL, Levin NW, et al. Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS. Kidney Int 2006; 69:1222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charra B, Calemard E, Ruffet M, et al. Survival as an index of adequacy of dialysis. Kidney Int 1992; 41:1286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buoncristiani U. Fifteen years of clinical experience with daily haemodialysis. Nephrol Dial Transplant 1998; 13 Suppl 6:148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kjellstrand C, Buoncristiani U, Ting G, et al. Survival with short-daily hemodialysis: association of time, site, and dose of dialysis. Hemodial Int 2010; 14:464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathew A, McLeggon JA, Mehta N, et al. Mortality and Hospitalizations in Intensive Dialysis: A Systematic Review and Meta-Analysis. Can J Kidney Health Dis 2018; 5:2054358117749531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           FHN Trial Group, Chertow GM, Levin NW, et al. In-center hemodialysis six times per week versus three times per week. N Engl J Med 2010; 363:2287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pierratos A, Ouwendyk M, Francoeur R, et al. Nocturnal hemodialysis: three-year experience. J Am Soc Nephrol 1998; 9:859.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lacson E Jr, Wang W, Lester K, et al. Outcomes associated with in-center nocturnal hemodialysis from a large multicenter program. Clin J Am Soc Nephrol 2010; 5:220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haroon S, Davenport A. Haemodialysis at home: review of current dialysis machines. Expert Rev Med Devices 2018; 15:337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Hejaili F, Kortas C, Leitch R, et al. Nocturnal but not short hours quotidian hemodialysis requires an elevated dialysate calcium concentration. J Am Soc Nephrol 2003; 14:2322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barua M, Hladunewich M, Keunen J, et al. Successful pregnancies on nocturnal home hemodialysis. Clin J Am Soc Nephrol 2008; 3:392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Su WS, Lekas P, Carlisle EJ, et al. Management of hypophosphatemia in nocturnal hemodialysis with phosphate-containing enema: a technical study. Hemodial Int 2011; 15:219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ing TS, Yu AW, Agrawal B, et al. Increasing plasma phosphorus values by enriching with phosphorus the "acid concentrate" of a bicarbonate-buffered dialysate delivery system. Int J Artif Organs 1992; 15:701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leypoldt JK, Kraus MA, Collins AJ. Optimizing serum total carbon dioxide concentration during short and nocturnal frequent hemodialysis using lactate as dialysate buffer base. Hemodial Int 2020; 24:470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lockridge R, Cornelis T, Van Eps C. Prescriptions for home hemodialysis. Hemodial Int 2015; 19 Suppl 1:S112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greene T, Daugirdas JT, Depner TA, et al. Solute clearances and fluid removal in the frequent hemodialysis network trials. Am J Kidney Dis 2009; 53:835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pierratos A, Francoeur R, Ouwendyk M. Delayed dialyzer reprocessing for home hemodialysis. Home Hemodial Int 2000; 4:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Twardowski ZJ. Dialyzer reuse-Part I: Historical perspective. Semin Dial 2006; 19:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kjellstrand CM, Blagg CR, Bower J, Twardowski ZJ. The Aksys personal hemodialysis system. Semin Dial 2004; 17:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faratro R, D'Gama C, Chan C. The use of alternative anti-coagulation strategies for a nocturnal home hemodialysis patient with heparin-induced thrombocytopenia. CANNT J 2008; 18:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bugeja A, Harris S, McCormick B, et al. Safety and Efficacy of Tinzaparin Anticoagulation during Nocturnal Hemodialysis. Am J Nephrol 2019; 50:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suri RS, Larive B, Sherer S, et al. Risk of vascular access complications with frequent hemodialysis. J Am Soc Nephrol 2013; 24:498.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pipkin M, Craft V, Spencer M, Lockridge RS Jr. Six years of experience with nightly home hemodialysis access. Hemodial Int 2004; 8:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eloot S, De Vos JY, Hombrouckx R, Verdonck P. How much is catheter flow influenced by the use of closed luer lock access devices? Nephrol Dial Transplant 2007; 22:3061.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hemmelgarn BR, Moist LM, Lok CE, et al. Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator. N Engl J Med 2011; 364:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayes WN, Tennankore K, Battistella M, Chan CT. Vascular access-related infection in nocturnal home hemodialysis. Hemodial Int 2014; 18:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xue H, Li NC, Lacson E Jr, et al. Catheter-related bacteremia and mortality in frequent nocturnal home hemodialysis. Hemodial Int 2015; 19:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kubabra H and. Different sites versus constant sites of needle insertion into arteriovenous fistulas for treatment by repeated dialysis. Dial Transplant 1979; 8:978.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Twardowski Z, Kubara H. Different sites versus constant sites of needle insertion into arteriovenous fistulas for treatment by repeated dialysis. Dial Transpl 1979; 8:978.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hashmi A, Cheema MQ, Moss AH. Hemodialysis patients' experience with and attitudes toward the buttonhole technique for arteriovenous fistula cannulation. Clin Nephrol 2010; 74:346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nesrallah GE, Cuerden M, Wong JH, Pierratos A. Staphylococcus aureus bacteremia and buttonhole cannulation: long-term safety and efficacy of mupirocin prophylaxis. Clin J Am Soc Nephrol 2010; 5:1047.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lok CE, Huber TS, Lee T, et al. KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update. Am J Kidney Dis 2020; 75:S1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pauly RP, Eastwood DO, Marshall MR. Patient safety in home hemodialysis: quality assurance and serious adverse events in the home setting. Hemodial Int 2015; 19 Suppl 1:S59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong B, Zimmerman D, Reintjes F, et al. Procedure-related serious adverse events among home hemodialysis patients: a quality assurance perspective. Am J Kidney Dis 2014; 63:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tennankore KK, d'Gama C, Faratro R, et al. Adverse technical events in home hemodialysis. Am J Kidney Dis 2015; 65:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pierratos A. Nocturnal home haemodialysis: an update on a 5-year experience. Nephrol Dial Transplant 1999; 14:2835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kennedy C, McGrath-Chong M, Arustei D, et al. A prototype line clamp for venous access bleeding in hemodialysis: A prospective cohort study. Hemodial Int 2019; 23:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoy CD. Remote Monitoring of Daily Nocturnal Hemodialysis. Hemodialysis Int 2001; 4:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heidenheim AP, Leitch R, Kortas C, et al. Patient monitoring in the London Daily/Nocturnal Hemodialysis Study. Am J Kidney Dis 2003; 42:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pierratos A. Daily nocturnal home hemodialysis. Kidney Int 2004; 65:1975.
          </a>
         </li>
         <li class="breakAll">
          MATCH-D group. Method to assess treatment choices for home dialysis (MATCH-D). 2011. http://www.homedialysis.org/files/pros/MatchD2009.pdf.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lockridge R Jr, Weinhandl E, Kraus M, et al. A Systematic Approach To Promoting Home Hemodialysis during End Stage Kidney Disease. Kidney360 2020; 1:993.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bowman BT. Transitional Care Units: Greater Than the Sum of Their Parts. Clin J Am Soc Nephrol 2019; 14:765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pauly RP, Gill JS, Rose CL, et al. Survival among nocturnal home haemodialysis patients compared to kidney transplant recipients. Nephrol Dial Transplant 2009; 24:2915.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishio-Lucar AG, Bose S, Lyons G, et al. Intensive Home Hemodialysis Survival Comparable to Deceased Donor Kidney Transplantation. Kidney Int Rep 2020; 5:296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cafazzo JA, Leonard K, Easty AC, et al. Patient-perceived barriers to the adoption of nocturnal home hemodialysis. Clin J Am Soc Nephrol 2009; 4:784.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan CT, Collins K, Ditschman EP, et al. Overcoming Barriers for Uptake and Continued Use of Home Dialysis: An NKF-KDOQI Conference Report. Am J Kidney Dis 2020; 75:926.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seshasai RK, Mitra N, Chaknos CM, et al. Factors Associated With Discontinuation of Home Hemodialysis. Am J Kidney Dis 2016; 67:629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paterson B, Fox DE, Lee CH, et al. Understanding Home Hemodialysis Patient Attrition: A Cohort Study. Can J Kidney Health Dis 2021; 8:20543581211022195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perl J, Na Y, Tennankore KK, Chan CT. Temporal Trends and Factors Associated with Home Hemodialysis Technique Survival in Canada. Clin J Am Soc Nephrol 2017; 12:1248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah N, Reintjes F, Courtney M, et al. Quality Assurance Audit of Technique Failure and 90-Day Mortality after Program Discharge in a Canadian Home Hemodialysis Program. Clin J Am Soc Nephrol 2017; 12:1259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jayanti A, Nikam M, Ebah L, et al. Technique survival in home haemodialysis: a composite success rate and its risk predictors in a prospective longitudinal cohort from a tertiary renal network programme. Nephrol Dial Transplant 2013; 28:2612.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1904 Version 36.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : United States Renal Data System. 2020 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. United States Renal Data System; National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 2020.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12490682" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Effect of dialysis dose and membrane flux in maintenance hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16609686" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1614043" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Survival as an index of adequacy of dialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9719222" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Fifteen years of clinical experience with daily haemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20854330" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Survival with short-daily hemodialysis: association of time, site, and dose of dialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29348924" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Mortality and Hospitalizations in Intensive Dialysis: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21091062" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : In-center hemodialysis six times per week versus three times per week.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9596084" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Nocturnal hemodialysis: three-year experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19965529" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Outcomes associated with in-center nocturnal hemodialysis from a large multicenter program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29656667" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Haemodialysis at home: review of current dialysis machines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12937309" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Nocturnal but not short hours quotidian hemodialysis requires an elevated dialysate calcium concentration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18308997" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Successful pregnancies on nocturnal home hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21395970" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Management of hypophosphatemia in nocturnal hemodialysis with phosphate-containing enema: a technical study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1493944" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Increasing plasma phosphorus values by enriching with phosphorus the "acid concentrate" of a bicarbonate-buffered dialysate delivery system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32779359" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Optimizing serum total carbon dioxide concentration during short and nocturnal frequent hemodialysis using lactate as dialysate buffer base.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25925819" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Prescriptions for home hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19339093" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Solute clearances and fluid removal in the frequent hemodialysis network trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Delayed dialyzer reprocessing for home hemodialysis
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16423181" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Dialyzer reuse-Part I: Historical perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15043619" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The Aksys personal hemodialysis system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19175190" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : The use of alternative anti-coagulation strategies for a nocturnal home hemodialysis patient with heparin-induced thrombocytopenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31434091" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Safety and Efficacy of Tinzaparin Anticoagulation during Nocturnal Hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23393319" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Risk of vascular access complications with frequent hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19379441" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Six years of experience with nightly home hemodialysis access.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17597088" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : How much is catheter flow influenced by the use of closed luer lock access devices?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21268722" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24467296" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Vascular access-related infection in nocturnal home hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25645402" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Catheter-related bacteremia and mortality in frequent nocturnal home hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Different sites versus constant sites of needle insertion into arteriovenous fistulas for treatment by repeated dialysis
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Different sites versus constant sites of needle insertion into arteriovenous fistulas for treatment by repeated dialysis
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20979942" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Hemodialysis patients' experience with and attitudes toward the buttonhole technique for arteriovenous fistula cannulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20413438" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Staphylococcus aureus bacteremia and buttonhole cannulation: long-term safety and efficacy of mupirocin prophylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32778223" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25925825" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Patient safety in home hemodialysis: quality assurance and serious adverse events in the home setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23993152" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Procedure-related serious adverse events among home hemodialysis patients: a quality assurance perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25441436" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Adverse technical events in home hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10570083" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Nocturnal home haemodialysis: an update on a 5-year experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30779306" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : A prototype line clamp for venous access bleeding in hemodialysis: A prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Remote Monitoring of Daily Nocturnal Hemodialysis
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12830446" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Patient monitoring in the London Daily/Nocturnal Hemodialysis Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15086951" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Daily nocturnal home hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15086951" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Daily nocturnal home hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35369547" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : A Systematic Approach To Promoting Home Hemodialysis during End Stage Kidney Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30917994" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Transitional Care Units: Greater Than the Sum of Their Parts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19584107" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Survival among nocturnal home haemodialysis patients compared to kidney transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32154451" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Intensive Home Hemodialysis Survival Comparable to Deceased Donor Kidney Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19339408" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Patient-perceived barriers to the adoption of nocturnal home hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32057468" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Overcoming Barriers for Uptake and Continued Use of Home Dialysis: An NKF-KDOQI Conference Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26709066" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Factors Associated With Discontinuation of Home Hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34178360" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Understanding Home Hemodialysis Patient Attrition: A Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28739576" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Temporal Trends and Factors Associated with Home Hemodialysis Technique Survival in Canada.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28739573" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Quality Assurance Audit of Technique Failure and 90-Day Mortality after Program Discharge in a Canadian Home Hemodialysis Program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24078644" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Technique survival in home haemodialysis: a composite success rate and its risk predictors in a prospective longitudinal cohort from a tertiary renal network programme.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
